PDS Biotechnology Corp Amortization of Debt Issuance Costs
PDS Biotechnology Corp (PDSB) reported Amortization of Debt Issuance Costs of $125.36 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2019-02-21
- PDS Biotechnology Corp amortization of debt issuance costs for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp amortization of debt issuance costs for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp amortization of debt issuance costs for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp amortization of debt issuance costs for the quarter ending 2018-03-31 was $125.36K, a 362.53% increase year-over-year.
- PDS Biotechnology Corp amortization of debt issuance costs for fiscal 2018 was $125.36K, a 15.63% increase from fiscal 2017.
- PDS Biotechnology Corp amortization of debt issuance costs for fiscal 2017 was $108.41K, a 19.39% increase from fiscal 2016.
- PDS Biotechnology Corp amortization of debt issuance costs for fiscal 2016 was $90.80K, a 4.07% decline from fiscal 2015.
- PDS Biotechnology Corp amortization of debt issuance costs for fiscal 2015 was $94.65K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $0.00 derived: sum of 2 quarters · filed 2019-02-21 | $0.00 derived: sum of 3 quarters · filed 2019-02-21 | $125.36K 10-K · filed 2019-02-21 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $125.36K 10-Q · filed 2018-11-01 | $152.46K derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $125.36K 10-Q · filed 2018-08-01 | $152.46K derived: sum of 3 quarters · filed 2019-02-21 | $179.56K derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-03-31 | $125.36K 10-Q · filed 2018-05-01 | $152.46K derived: sum of 2 quarters · filed 2019-02-21 | $179.56K derived: sum of 3 quarters · filed 2019-02-21 | $206.66K derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-12-31 | $27.10K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $54.20K derived: sum of 2 quarters · filed 2019-02-21 | $81.31K derived: sum of 3 quarters · filed 2019-02-21 | $108.41K 10-K · filed 2019-02-21 |
| 2017-09-30 | $27.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $54.20K derived: sum of 2 quarters · filed 2018-11-01 | $81.31K 10-Q · filed 2018-11-01 | $108.41K derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $27.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $54.20K 10-Q · filed 2018-08-01 | $81.31K derived: sum of 3 quarters · filed 2018-08-01 | $105.16K derived: sum of 4 quarters · filed 2018-08-01 |
| 2017-03-31 | $27.10K 10-Q · filed 2018-05-01 | $54.20K derived: sum of 2 quarters · filed 2018-05-01 | $78.06K derived: sum of 3 quarters · filed 2018-05-01 | $96.89K derived: sum of 4 quarters · filed 2018-05-01 |
| 2016-12-31 | $27.10K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $50.95K derived: sum of 2 quarters · filed 2018-03-01 | $69.78K derived: sum of 3 quarters · filed 2018-03-01 | $90.80K 10-K · filed 2018-03-01 |
| 2016-09-30 | $23.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $42.68K derived: sum of 2 quarters · filed 2017-11-01 | $63.70K 10-Q · filed 2017-11-01 | $158.35K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $18.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $39.85K 10-Q · filed 2017-08-01 | $134.50K derived: sum of 3 quarters · filed 2018-03-01 | $134.50K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $21.02K 10-Q · filed 2017-05-03 | $115.66K derived: sum of 2 quarters · filed 2018-03-01 | $115.66K derived: sum of 3 quarters · filed 2018-03-01 | $115.66K derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $94.65K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $94.65K derived: sum of 2 quarters · filed 2018-03-01 | $94.65K derived: sum of 3 quarters · filed 2018-03-01 | $94.65K 10-K · filed 2018-03-01 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $0.00 derived: sum of 2 quarters · filed 2016-11-01 | $0.00 10-Q · filed 2016-11-01 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $0.00 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-03 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-02 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |